Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis

Thoracic Cancer

Volumn 2, Issue 3, 2011, Pages 101-108

  Zhang, Xiao Hang ^a,b   Li, Cheng ^a,b   Dai, Chen Fei ^a   Zhou, Bao Sen ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b University of Liaoning Province   (China)

Author keywords

Epidermal growth factor receptor; Meta analysis; Mutation; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ARTICLE; DRUG EFFICACY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TREATMENT RESPONSE; WILD TYPE;

EID: 84861396727     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2011.00051.x     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E etal. Cancr statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Schiller JH, Harrington D, Belani CP etal. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
3. Brambilla E, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classfication of lung tumors. Eur Respir J 2001; 18: 1059-68.
4. Asahina H, Yamazaki K, Kinoshita I etal. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95: 998-1004.
5. Scagliotti GV, Selvaggi G, Novello S etal. The biology of epidermal growth factor receptor in the lung cancer. Clin Cancer Res 2004; 10: 4227s-32s.
6. Bunn JPA, Franklin WA. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29 (Suppl. 14): 38-44.
7. Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemicaland fluorescence in situ hybridization study. Cancer 2005; 103: 1265-73.
8. Hirsh FR, Varella-Garcia M, Bunn PA Jr. etal. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on progonsis. J Clin Oncol 2003; 21: 3798-807.
9. Fukuoka M, Yano S, Giaccone G etal. Multiinstitutional randomized phase? Trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL trial). J Clin Oncol 2003; 21: 2237-46.
10. Kris MG, Natale RB, Herbst RS etal. Efficacy of gefitib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
11. Perez-Soler R, Chachona A, Hammond LA etal. Determinants of tumor response and survival with erlotinib in pateints with non-small-cell lung cancer. J Chin Oncol 2004; 22: 3238-47.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T etal. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
13. Thatcher N, Chang A, Parikh P etal. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37.
14. Carlson JJ, Garrison LP etal. Epidermal growth factor receptor genomic variation in NSCLC patients receving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2009; 135: 1483-93.
15. Tomizawa Y, Iijima H, Sunaga N etal. Clinicopathologic significance of the mutations of the epedermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 6816-22.
16. Xu JM, Han Y, Duan HQ etal. EGFR mutation and HER2/3 protein expression and clinical outcome in Chinese advancednon-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol 2009; 135: 711-82.
17. Shih J-Y, Gow C-H, Yu C-J etal. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006; 118: 963-9.
18. Takano T, Ohe Y, Tsuta K etal. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-smass cell lung cancer treated with gefitinib. Clin Cancer Res 2007; 13: 5385-90.
19. Wu J-Y, Yu C-J, Shih J-Y etal. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 2009; 67: 348-54.
20. Chou Y-Y, Chiu C-H, Li L-H etal. Mutation in the turosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 3750-7.
21. Mitsudomi T, Kosaka T, Endoh H etal. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-20.
22. Han S-W, Kim T-Y, Hwang PG etal. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2403-501.
23. Zhang X-T, Li L-Y, Mu X-L etal. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 2005; 16: 1334-42.
24. Niho S, Kubota K, Goto K etal. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006; 24: 64-9.
25. Hsieh M-H, Fang Y-F, Chang W-C etal. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 2006; 53: 311-22.
26. Oshita F, Matsukuma S, Yoshihara M etal. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer 2006; 95: 1070-5.
27. Rosell R, Lchinose Y, Taron M etal. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 2005; 50: 25-33.
28. Satouchi M, Negoro S, Funada Y etal. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer 2007; 96: 1191-6.
29. Sone T, Kasahara K, Kimura H etal. Comparative Analysis of Epedermal Growth Factor Receptor Mutations and Gene Amplification As Predictors of Gefitinib Efficacy in Japanese Patients With Nonsmall Cell Lung Cancer. American Cancer Society. 2007; 1836-44.
30. Liang Z, Zhang J, Zeng X, Gao J, Wu S, Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 2010; 10: 376-84.
31. Bunn PA Jr, Dziadziuszko R, Varella-garcia M etal. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 2006; 12: 3652-6.
32. Wu Y-L, Zhong W-Z etal. Epidermal growth factor receptor mutation and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patients data from six medical centers in mainland China. J Thorac Oncol 2007; 2: 430-9.
33. Pham D, Kris MG, Riely GJ etal. Use of cigarette-smoking history to estimate the likehood of mutations in epidermal growth factor factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006; 24: 1700-4.
34. Wang S, An T, Wang J, Zhao J etal. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 1324-30. Epub 2010 Feb 9.
35. Riely GJ, Politi KA, Miller VA etal. Update on epidermal growth factor receptor mutation in non-small cell lung cancer. Clin Cancer Res 2006; 12: 7232-41.